When the world longs for a return to normal life after more than a year of living through the pandemic, countries rush to provide vaccines that should slow – and hopefully stop – the spread of the pandemic. coronavirus.
Successful delivery will depend on a number of factors, including the manufacture and transportation of billions of doses, ensuring that rich nations do not monopolize the world’s vaccine offerings, and, crucially, actually put doses into people’s arms.
The graphs and charts below will be updated to show the latest data on the largest vaccination rollout in history, in the United States and around the globe.
There are noticeable differences from one state to another in how vaccines are given to people.
The first two vaccines approved in order emergency use in the United States, developed by companies Pfizer / BioNTech and Modern, are designed to be given in two doses several weeks apart. U Johnson & Johnson the vaccine authorized for use in late February requires a single dose. So vaccinating everyone in the United States would mean giving somewhere between 100 and 200 doses per 100 people in every state and territory – or a total of between 330 million and 660 million doses nationwide. It’s a huge logistical challenge.
As the Biden administration has taken the lead, promising stronger federal coordination of vaccine distribution, the number of strokes given each day is steadily increasing, reaching a peak of more than 3 million doses per day. April. In May, in the face of a sharp drop in the number of people taking strikes, Biden announced a new strategy with the goal of vaccinating the hardest-to-reach communities, moving from mass vaccination centers to more mobile clinics and pharmacy walking appointments. However, there are concerns that the vaccination unit will be poorer people and community of color daretu.
Search or navigate through this table to find out how your state or territory is performing on these key vaccine rollout measures.
Vaccine launch history
This chart shows the number of vaccines administered per 100 people per state since the beginning of 2021. The top three states and U.S. national numbers are highlighted. Type the name of any other US state or territory in the search bar and select it to add to the chart.
This chart shows the daily number of vaccine doses given to people across the nation since the beginning of 2021. Due to peaks in the data due to lags in reporting, the line shows the rotating average of 7 days of given doses give a clearer idea of whether the rollout accelerates or slows down.
Rollout vaccines by nation
More countries appeared on this chart showing vaccine doses given per 100 people because these numbers are more widely reported.
Most of the countries with the highest vaccination rates so far have a very small population. The United States is ahead of most other major nations in vaccine development. Search or navigate through this table to see how this nation works.
Vaccine launch schedule
This chart shows the number of vaccines administered per 100 people per country since the beginning of 2021. Enter the name of any nation in the search bar and select to compare its timeline with the United States and the other top three countries. leading the rollout of vaccines in the world. Only countries that have started their vaccination campaigns will appear.
This graph shows the reported daily number of doses of vaccine given to people around the world. Due to the peaks due to lags in signaling, the line showing the 7-day rotating average of the given doses gives a clearer idea of whether the launch accelerates or slows down.
Situation of the main vaccines
This table documents the status of major COVID-19 vaccines, showing authorizations for use in the United States and other selected markets, plus pricing from information on purchase agreements. compiled by UNICEF, where available.
Vaccines from Pfizer / BioNTech and Modern, with results from clinical trials indicating that they are more than 90% effective in the prevention of diseases, they are based on new technology which provides an RNA sequence that causes our own cells to produce viral proteins, triggering an immune response.
The disadvantage is that these vaccines are more expensive than those made by splicing genetic material from the coronavirus into an inactivated version of another virus, such as those produced by the Anglo-Swedish company AstraZeneca, based on research from Oxford University, Johnson & Johnson, is from Russia Gamaleya Research Institute.
Other major vaccines are based on inactivated versions of the coronavirus, a long-standing approach to making vaccines, or protein subunits from the virus.
Jeremy Singer-Vine helped refer to this story.